Clinical Trial Update: Study of Disitamab Vedotin and Anlotinib in Patients With HR-Negative, HER2-Low-Expressing Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for disitamab vedotin with anlotinib in HR-negative, HER2-low-expressing metastatic breast cancer is ongoing with no current statu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Anlotinib (anlotinib)
• Disitamab Vedotin (disitamab vedotin)

Snippet

Sponsor: Qilu Hospital of Shandong University | Conditions: Breast Cancer | Phase 2 | Status: UNKNOWN